DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Savolitinib
Savolitinib
MET Or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib
Gu Studies
Crusader Newsletter Q2 2021 Research Edition
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: the VIKTORY Umbrella Trial
2018 Interim Results
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Therapeutic Strategies in MET Exon 14 Skipping Mutated Non-Small Cell
Download Presentation (PDF)
Efficacy of Savolitinib Vs Sunitinib in Patients with MET-Driven Papillary Renal Cell Carcinoma the SAVOIR Phase 3 Randomized Clinical Trial
Small-Cell Lung Cancer: Evidence to Date Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaid
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
MEK Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Stembook 2018.Pdf
Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer
First-In-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced
Learning from Hereditary Kidney Cancer Syndromes
Top View
Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology Into New Opportunities
Dctd Programs and Initiatives (2013-2017) Biometric Research Program 46
NCI Formulary & NCI-MATCH Trial
Targeting the MET-Signaling Pathway in Non- Small–Cell Lung Cancer: Evidence to Date
New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: a Focus on Novel Driver Kinases
October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Single-Cell Transcriptional Changes Associated with Drug Tolerance and Response to Combination Therapies in Cancer
WO 2021/062244 Al 01 April 2021 (01.04.2021) W IP O I PCT
First-In-Human Phase I Study of The
Cancer Bronchique Non À Petites Cellules (2021)
Clinical Trials Appendix Q2 2015 Results Update
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
Clinical Trials Appendix Q1 2021 Results Update
Development and Characterization of Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases
Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors in NSCLC
Study Protocol Astrazeneca Savolitinib (AZD6094) 19 December 2018 D5082C00003 6.0
JP Morgan Global China Summit 2019
Comprehensive Review of Targeted Therapy for Colorectal Cancer
Biomarker-Based Phase II Trial of Savolitinib in Patients with Advanced Papillary Renal Cell Cancer Toni K
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri